Liposome-mediated peptide loading of MHC-DR molecules in vivo.
Amino acid residues 3-15 of mycobacterial HSP60 define a dominant T-cell epitope for HLA-DR3+ve humans and Mamu-DR3+ve rhesus monkeys. Our results show that Mamu-DR3 molecules on PBMC can be efficiently loaded in vivo with the above-mentioned peptides when they are intravenously injected encapsulated in liposomes, but not in the free form. Mamu-DR3 loading is abolished by encapsulation of a nonstimulatory peptide. These results have implications for the delivery of therapeutic peptides in vivo.
t Hart
B A
BA
Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, The Netherlands. hart@bprc.nl
Elferink
D G
DG
Drijfhout
J W
JW
Storm
G
G
van Blooijs
L
L
Bontrop
R E
RE
de Vries
R R
RR
D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects / Q000276:immunology; D004337:Drug Carriers; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000008:administration & dosage* / Q000187:drug effects / Q000378:metabolism; D007275:Injections, Intravenous; D008081:Liposomes / Q000008:administration & dosage / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects; D008253:Macaca mulatta; D008297:Male; D010455:Peptides / Q000008:administration & dosage* / Q000276:immunology* / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D004337:Drug Carriers; D000949:Histocompatibility Antigens Class II; D008081:Liposomes; D010455:Peptides